FindTrial
Sign In

To find out simple technique in order to assess the fibrosis changes in the liver in Liver disease (Hepatitis B,Hepatitis C and NAFLD).

Cost effective non invasive diagnostic modalities and predictive model for development and progression of fibrosis among patients with Hepatitis B, Hepatitis C infection or non alcoholic fatty liver disease: A hospital based retrospective followed by prospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/02/012238
Enrollment
3000
Registered
2018-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified Health Condition 2: null- Hepatitis B,Hepatitis C and Non Alcoholic Fatty Liver Disease Health Condition 3: K769- Liver disease, unspecified

Interventions

Intervention1: Hepatitis B patients: Biopsy proven Hepatitis B virus infected cases will be followed for the period of 5 years Intervention2: Hepatitis C patients: Biopsy proven Hepatitis C virus infe

Sponsors

Institute of liver and Biliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 years and above Patients who underwent liver biopsy with underlying etiology as HBV, HCV, NASH or cryptogenic or ALD (inpatient or outpatient) Metavir Fibrosis Score F0-3 for prospective study design

Exclusion criteria

Exclusion criteria: Not willing to participate in the study Patients with chronic liver disease of other

Design outcomes

Primary

MeasureTime frame
Incidence rate of development & progression of fibrosis will be calculated.Timepoint: 5 years—

Secondary

MeasureTime frame
A predictive model for development & progression of fibrosisTimepoint: 5 years;Cost effective analysis for non invasive markersTimepoint: 5 years;Validation of Non invasive markers for development and progression of fibrosisTimepoint: 5 years—

Countries

India

Contacts

Public ContactDr Ajeet Singh Bhadoria

Institute of Liver and Biliary Sciences

ajeetsinghbhadoria@gmail.com01146300000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026